Robert N. Fried - 19 Feb 2026 Form 4 Insider Report for Niagen Bioscience, Inc. (NAGE)

Role
Chief Executive Officer, Director
Signature
/s/ Jeong James Lee, Attorney-in-Fact
Issuer symbol
NAGE
Transactions as of
19 Feb 2026
Net transactions value
$0
Form type
4
Filing time
24 Feb 2026, 16:44:59 UTC
Previous filing
09 Apr 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fried Robert N Chief Executive Officer, Director 10900 WILSHIRE BLVD. SUITE 600, LOS ANGELES /s/ Jeong James Lee, Attorney-in-Fact 24 Feb 2026 0001417952

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAGE Employee Stock Options (right to buy) Award $0 +503,937 $0.000000 503,937 19 Feb 2026 Common Stock 503,937 $4.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to the option shall vest on each anniversary of the grant date.